GCP
GSA Capital Partners Portfolio holdings
AUM
$1.43B
1-Year Return
20.34%
This Quarter Return
+12.71%
1 Year Return
+20.34%
3 Year Return
+63.52%
5 Year Return
+120%
10 Year Return
+237.47%
AUM
$1.43B
AUM Growth
+$322M
(+29%)
Cap. Flow
+$246M
Cap. Flow
% of AUM
17.2%
Top 10 Holdings %
Top 10 Hldgs %
6.36%
Holding
2,241
New
645
Increased
572
Reduced
474
Closed
546
Top Buys
| 1 |
NVIDIA
NVDA
|
+$16M |
| 2 |
Apple
AAPL
|
+$13.6M |
| 3 |
Microsoft
MSFT
|
+$13M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$8.08M |
| 5 |
JPMorgan Chase
JPM
|
+$7.42M |
Top Sells
| 1 |
CSX Corp
CSX
|
+$4.47M |
| 2 |
Blackstone
BX
|
+$4.34M |
| 3 |
WK Kellogg Co
KLG
|
+$3.21M |
| 4 |
Cal-Maine
CALM
|
+$2.92M |
| 5 |
nVent Electric
NVT
|
+$2.69M |
Sector Composition
| 1 | Technology | 18.52% |
| 2 | Financials | 15.35% |
| 3 | Healthcare | 14.19% |
| 4 | Industrials | 11.58% |
| 5 | Consumer Discretionary | 11.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Myriad Genetics
MYGN
$642M
| $60K | ﹤0.01% |
+11,215
| New | +$60K |
|
1652
Karyopharm Therapeutics
KPTI
$53.8M
| $60K | ﹤0.01% |
+13,894
| New | +$60K |
|
1653
AEye
LIDR
$106M
| $60K | ﹤0.01% |
58,079
-3,416
| -6% | -$3.53K |
|
1654
Lexeo Therapeutics
LXEO
$281M
| $58K | ﹤0.01% |
+14,528
| New | +$58K |
|
1655
Prelude Therapeutics
PRLD
$67.4M
| $58K | ﹤0.01% |
+71,378
| New | +$58K |
|
1656
W&T Offshore
WTI
$261M
| $58K | ﹤0.01% |
+35,031
| New | +$58K |
|
1657
Quince Therapeutics
QNCX
$86.5M
| $56K | ﹤0.01% |
33,818
-2,809
| -8% | -$4.65K |
|
1658
Inspirato
ISPO
$37.7M
| $54K | ﹤0.01% |
+15,903
| New | +$54K |
|
1659
Ceragon Networks
CRNT
$180M
| $53K | ﹤0.01% |
+21,550
| New | +$53K |
|
|
OKUR
1660
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$33.8M
| $52K | ﹤0.01% |
+21,765
| New | +$52K |
|
1661
SelectQuote
SLQT
$339M
| $50K | ﹤0.01% |
+20,946
| New | +$50K |
|
1662
Olaplex Holdings
OLPX
$941M
| $49K | ﹤0.01% |
34,935
-695,536
| -95% | -$976K |
|
1663
Vuzix
VUZI
$176M
| $47K | ﹤0.01% |
16,059
-129,023
| -89% | -$378K |
|
1664
InflaRx
IFRX
$107M
| $46K | ﹤0.01% |
+57,951
| New | +$46K |
|
1665
OmniAb
OABI
$226M
| $46K | ﹤0.01% |
26,174
-99,278
| -79% | -$174K |
|
1666
HF Foods Group
HFFG
$171M
| $44K | ﹤0.01% |
+13,957
| New | +$44K |
|
1667
Perfect Corp
PERF
$190M
| $44K | ﹤0.01% |
19,302
-4,299
| -18% | -$9.8K |
|
1668
Atossa Therapeutics
ATOS
$103M
| $42K | ﹤0.01% |
+51,029
| New | +$42K |
|
1669
Rimini Street
RMNI
$414M
| $40K | ﹤0.01% |
+10,718
| New | +$40K |
|
1670
Hain Celestial
HAIN
$176M
| $39K | ﹤0.01% |
25,636
-292,690
| -92% | -$445K |
|
1671
Trinseo
TSE
$81.6M
| $39K | ﹤0.01% |
12,450
-92,622
| -88% | -$290K |
|
1672
Assertio
ASRT
$77.5M
| $38K | ﹤0.01% |
+60,000
| New | +$38K |
|
1673
Aterian
ATER
$9.5M
| $38K | ﹤0.01% |
+23,095
| New | +$38K |
|
1674
Acumen Pharmaceuticals
ABOS
$81.8M
| $37K | ﹤0.01% |
+32,103
| New | +$37K |
|
1675
PLAYSTUDIOS Inc
MYPS
$120M
| $37K | ﹤0.01% |
+27,971
| New | +$37K |
|